COCP Valuation

Cocrystal Pharma Inc

Add to Watchlist

Advanced Chart

1.270

+0.055(4.527%)1D

Overview
Forecast
Valuation
Earnings

COCP Relative Valuation

COCP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COCP is overvalued; if below, it's undervalued.

Historical Valuation

Cocrystal Pharma Inc (COCP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.91. The fair price of Cocrystal Pharma Inc (COCP) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.22

Fair

-1.55

Trailing

Forward

0.00

EV/EBITDA

Cocrystal Pharma Inc. (COCP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.17. The thresholds are as follows: Strongly Undervalued below -0.52, Undervalued between -0.52 and -0.17, Fairly Valued between 0.52 and -0.17, Overvalued between 0.52 and 0.86, and Strongly Overvalued above 0.86. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.06

EV/EBIT

Cocrystal Pharma Inc. (COCP) has a current EV/EBIT of -1.06. The 5-year average EV/EBIT is -0.94. The thresholds are as follows: Strongly Undervalued below -5.69, Undervalued between -5.69 and -3.31, Fairly Valued between 1.43 and -3.31, Overvalued between 1.43 and 3.80, and Strongly Overvalued above 3.80. The current Forward EV/EBIT of -1.06 falls within the Historic Trend Line -Fairly Valued range.

0.00

Cocrystal Pharma Inc. (COCP) has a current PS of 0.00. The 5-year average PS is 18.43. The thresholds are as follows: Strongly Undervalued below -30.88, Undervalued between -30.88 and -6.23, Fairly Valued between 43.09 and -6.23, Overvalued between 43.09 and 67.74, and Strongly Overvalued above 67.74. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Cocrystal Pharma Inc. (COCP) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.07. The thresholds are as follows: Strongly Undervalued below -6.64, Undervalued between -6.64 and -3.85, Fairly Valued between 1.72 and -3.85, Overvalued between 1.72 and 4.51, and Strongly Overvalued above 4.51. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Cocrystal Pharma Inc. (COCP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Cocrystal Pharma Inc (COCP) has a current Price-to-Book (P/B) ratio of 2.32. Compared to its 3-year average P/B ratio of 1.07 , the current P/B ratio is approximately 116.27% higher. Relative to its 5-year average P/B ratio of 1.15, the current P/B ratio is about 102.32% higher. Cocrystal Pharma Inc (COCP) has a Forward Free Cash Flow (FCF) yield of approximately -77.72%. Compared to its 3-year average FCF yield of -88.77%, the current FCF yield is approximately -12.45% lower. Relative to its 5-year average FCF yield of -60.53% , the current FCF yield is about 28.40% lower.

2.32

P/B

Median3y

1.07

Median5y

1.15

-77.72

FCF Yield

Median3y

-88.77

Median5y

-60.53

Competitors Valuation Multiple

The average P/S ratio for COCP's competitors is 3.92, providing a benchmark for relative valuation. Cocrystal Pharma Inc Corp (COCP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Cellectar Biosciences Inc

Minerva Neurosciences Inc

Performance Decomposition

Market capitalization of COCP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of COCP in the past 1 year is driven by Unknown.